Hims & Hers Health stock rises as FDA-approved Wegovy and Ozempic come back to market

Traders Union
All News
Financial News
Hims & Hers Health gains 1.66% today

Highlights

Hims & Hers Health faces a federal investigation and Novo Nordisk partnership loss over alleged unauthorized semaglutide sales and misleading weight-loss drug marketing.
The company reported a customer data breach but relaunched FDA-approved GLP-1 drugs via a new subscription-based weight loss program.
Shares trade below major moving averages, with technical indicators favoring continued bearish momentum and a likely price range of $18.00–$21.00 over the next week.

Regulatory scrutiny and data breach disrupt sentiment after partner exit

Recent developments for Hims & Hers Health include the initiation of a federal investigation after Novo Nordisk ended its partnership with the company due to alleged unauthorized sales and misleading marketing of weight-loss drugs containing semaglutide, which raised patient safety concerns. Additionally, Hims & Hers Health reported a data breach after support tickets were stolen from a third-party customer service platform. The company recently restored FDA-approved GLP-1 drugs like Wegovy and Ozempic to its platform as part of a new subscription-based weight loss program.

Bearish bias persists as momentum indicators signal weak selling exhaustion

On the technical side, HIMS trades well below its short-term MA-20, medium-term MA-50, and long-term MA-200, maintaining a bearish structure across all timeframes. Immediate resistance is seen at the Ichimoku Kijun level of $20.93. Daily momentum indicators show weak downside momentum, with MACD and ADX reflecting ongoing weakness. The RSI stands just below neutral at 45, while Stoch RSI and CCI point to mildly oversold conditions, and BBP is significantly negative, indicating sellers continue to dominate intraday activity. Awesome Oscillator remains neutral and does not reinforce the prevailing trend, while price action after a gap-up open has since retraced to approach the session's low, highlighting intraday pressure despite moderate volatility. Oscillators signal short-term selling exhaustion amid persistent weakness.

Downside risks predominate as narrow resistance caps short-term outlook

Over the next five trading days, HIMS is likely to remain within a volatility band of $18.00 – $21.00 relative to current levels. The probability of an upward move is very low (less than 20%), so a further decline remains the more likely path. The base scenario is continued sideways movement just below resistance, while a bullish outcome would require a breakout above the $20.90 – $21.00 zone. If support around $18.00 is breached, a deeper short-term decline is possible, with technical risks skewed to the downside and little sign of an imminent reversal.

Viktoras Karapetjanc, expert at Traders Union, believes Hims & Hers Health is under significant pressure from both regulatory probes and technical weakness. He sees recent negative news and persistent bearish indicators as key factors capping short-term upside, with resistance near $20.90 – $21.00 and technical risks skewed to the downside. Despite a challenging outlook, Karapetjanc thinks the company’s restoration of FDA-approved drugs and new subscription model could support sentiment if legal issues stabilize. Still, momentum remains weak and volatility may persist around current levels. "A clear breakout above $21.00 is required to shift sentiment, but for now, I favor caution until regulatory and technical headwinds ease."

Earlier, analysts noted that Hims & Hers Health was experiencing persistent downside momentum and elevated risk due to ongoing legal and revenue headwinds. The latest developments, including fresh regulatory scrutiny and continued technical weakness, reinforce the prevailing bearish structure, making close monitoring of the $18.00 support level crucial for assessing the next significant move.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.